Partial
Patient Risk:
Moderate
Summary
Most core mechanistic and labeled-use claims (CGRP receptor antagonist; preventive treatment of episodic migraine in adults; approved dosing as once-daily oral therapy) are consistent with the provided label excerpts. Several efficacy, adverse reaction, and episodic migraine-definition claims are not sufficiently supported by the provided label text and important labeled safety/administration details are omitted.
Category Scores
Accurate Statements
Qulipta is indicated for the preventive treatment of migraine in adults (including episodic migraine).
Indications and Usage (Section 1): “QULIPTA is indicated for the preventive treatment of migraine in adults.”; Dosage/Administration episodic migraine dosing (Section 2.1) supports episodic migraine use.
Qulipta (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Clinical Pharmacology — Mechanism of Action (Section 12.1): “Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.”
Qulipta blocks the CGRP receptor.
Mechanism of Action (Section 12.1): “CGRP receptor antagonist.” (Label supports antagonism at the receptor; the phrasing ‘blocks’ is consistent with antagonist mechanism.)
Unsupported Statements
In clinical trials, Qulipta significantly reduced monthly migraine days compared with placebo.
The provided label excerpts confirm efficacy was demonstrated in placebo-controlled studies (Section 14.1) but do not provide the specific “significantly reduced monthly migraine days” statement or comparative magnitude for the specific trial referenced.
In one 12-week study, patients taking Qulipta experienced a reduction of approximately 4.2 to 4.9 monthly migraine days versus 1.9 to 2.1 days for placebo.
No numerical results for the cited 12-week study with those exact values are present in the provided label text excerpts.
Common side effects of Qulipta reported in clinical trials included upper respiratory infection, nausea, and fatigue.
The provided label excerpt (Section 6.1) lists common adverse reactions as nausea, constipation, and fatigue/somnolence. “Upper respiratory infection” is not included in the provided excerpt.
Episodic migraine is generally defined as having fewer than 15 migraine days per month.
The provided label excerpts do not include this definition.
Qulipta is manufactured by AbbVie Inc.
The provided label excerpts do not include manufacturer information.
Qulipta received FDA approval on September 27, 2021.
The provided label excerpts do not include an approval date.
Contradictions
Important Omissions
Boxed warning status (if any), contraindication details, and key warnings/precautions including hypersensitivity (anaphylaxis/dyspnea/rash/pruritus/urticaria/facial edema), hypertension, and Raynaud’s phenomenon with monitoring/discontinuation guidance.
Importance:
High
Dosage instructions for episodic migraine (10 mg, 30 mg, or 60 mg once daily) and the ‘with or without food’ administration statement; the AI claims did not provide the actual dosing range or administration guidance.
Importance:
Moderate
Drug interaction and dosage modification guidance for strong/ moderate/weak CYP3A4 inhibitors and inducers, and OATP inhibitors (including specific recommended QULIPTA dosages with concomitant drugs and monitoring for reduced efficacy).
Importance:
High
Use in specific populations: pregnancy/lactation statements, pediatric not established, geriatric uncertainty, and renal/hepatic impairment dosing/avoidance recommendations.
Importance:
Moderate
Labeled adverse reaction profile beyond the listed ‘common side effects’ (e.g., constipation; liver enzyme elevations; and immune/vascular postmarketing events).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because the response omits key boxed/warning/precaution content and does not address labeled contraindications beyond a general lack of safety detail, it could lead to insufficient monitoring for hypersensitivity, hypertension, and Raynaud’s phenomenon. Omission of drug interaction dosage-modification guidance could increase risk of inappropriate dosing with CYP3A4 inhibitors/inducers and OATP inhibitors.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Primary Issue
Several efficacy/side-effect numerical and qualitative claims and the episodic migraine definition are not supported by the provided label excerpts, and the response omits critical labeled warnings/precautions and drug interaction/dosing modification information.
Suggested Improvement
Limit claims to label-supported statements from the provided prescribing information (e.g., indicated for preventive treatment of migraine in adults; atogepant is a CGRP receptor antagonist). Avoid unsupported numeric trial results and ‘upper respiratory infection’ as a common AE unless supported by the label text provided. Include key warnings/precautions (hypersensitivity, hypertension, Raynaud’s phenomenon) and summarize major interaction/dose modification guidance (CYP3A4 inhibitors/inducers; OATP inhibitors), plus the labeled episodic dosing range and administration ‘with or without food’.